


CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listings of claims in the application:


1-3. (canceled)

4. (currently amended) The A crystalline ethyl acetate solvate of carvedilol of claim 3 characterized by a PXRD pattern having peaks at about 5.8, 6.5, 7.3, 10.7, 11.1, 11.5, 13.1, 13.7, 16.0, 16.8, 17.7, 18.5, 23.0, and 30.5±0.2 degrees two-theta wherein the PXRD pattern is substantially as follows:




5. (canceled)

6. (currently amended) ~~The A~~ crystalline ethyl acetate solvate of carvedilol of claim 5 characterized by a PXRD pattern having peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta and a DSC thermogram having peaks at about 74° C and 112° C wherein the DSC thermogram is substantially as follows:




7-8. (canceled)

9. (currently amended) ~~The A~~ crystalline ethyl acetate solvate of carvedilol of claim 8 characterized by a PXRD pattern having peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta and a DSC thermogram having peaks at about 74° C and 112° C wherein the DSC thermogram is substantially as follows:



and further characterized by a FTIR spectrum having peaks at about 613, 720, 740, 994, 1100, 1125, 1228, 1257, 1286, 1441, 1454, 1508, 1589, 1737, 2840, 2911, 2935, 3281, 3389, and 3470 cm^{-1} wherein the FTIR spectrum is substantially as follows:



10-29. (canceled)